Vanda Pharmaceuticals Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Vanda Pharmaceuticals Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.0 times its market value (net cash). Higher than 88% of Healthcare companies in United States.
- Cash Locked Ratio: For every $100 of sales, $6 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $1 from others' credit three years earlier. Less money tied up than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-60.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 75% of Healthcare companies in United States.
Cash Locked Ratio
$6For every $100 of sales, $6 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $1 from others' credit three years earlier.
Less money tied up than 85% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 0/3Sales grew in 2 of the last 3 years; profit grew in 0 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 15%
Sales fell 15% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-15% / -23%In 3 years sales changed by -15% while total assets changed by -23%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-19.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 54% of Healthcare companies in United States.
Cash Cushion Ratio
1.0× cashCash, after subtracting all debt, is 1.0 times its market value (net cash).
Higher than 88% of Healthcare companies in United States.
Tangible Assets Ratio
76%Of every $100 the company owns, $76 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 57% of Healthcare companies in United States.
Tangible Net Worth Ratio
64%Of every $100 of net worth, $64 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 54% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Vanda Pharmaceuticals Inc. made a loss over the last year. Vanda Pharmaceuticals Inc. owes $0.47 for every $1 it owns. Vanda Pharmaceuticals Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossVanda Pharmaceuticals Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.11The share price is 1.11 times Vanda Pharmaceuticals Inc.'s book value per share, lower than 77% of Healthcare companies in United States.
Market cap
$245 MThe total market value of all of Vanda Pharmaceuticals Inc.'s shares at today's price (share price × number of shares), smaller than 55% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$220 MWhat Vanda Pharmaceuticals Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.64Net worth divided by the number of shares. The share price of $4.05 is 1.1 times this, which is the P/B above.
Return on equity (ROE)
-77.8%Vanda Pharmaceuticals Inc. lost 77.8% of its shareholders' money over the last year, lower than 64% of Healthcare companies in United States.
Owes vs Owns
0.47×Vanda Pharmaceuticals Inc. owes $0.47 for every $1 it owns (low), higher than 53% of Healthcare companies in United States.
Dividend yield
NoneVanda Pharmaceuticals Inc. does not currently pay a dividend.
Revenue growth
+9%Revenue rose 9% in the year to Dec 2025, and shrank 5% a year on average over 3 years.
Profit growth
LossVanda Pharmaceuticals Inc. made a loss in each of the last two years.
Profit margin
-102.0%Vanda Pharmaceuticals Inc. lost $102 for every $100 of revenue.
Cash vs debt
Net cashVanda Pharmaceuticals Inc. held $251 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Vanda Pharmaceuticals Inc.: $245 M ÷ $220 M (30 Jun 2026) = 1.1.
What is Vanda Pharmaceuticals Inc.'s return on equity?
Vanda Pharmaceuticals Inc. lost 77.8% of its shareholders' money over the last year, lower than 64% of Healthcare companies in United States.
How much does Vanda Pharmaceuticals Inc. owe compared with what it owns?
Vanda Pharmaceuticals Inc. owes $0.47 for every $1 it owns (low), higher than 53% of Healthcare companies in United States.
Does Vanda Pharmaceuticals Inc. pay a dividend?
No. Vanda Pharmaceuticals Inc. does not currently pay a dividend.
Is Vanda Pharmaceuticals Inc.'s revenue growing?
Revenue rose 9% in the year to Dec 2025, and shrank 5% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.